These studies showed that anti-TGFβ antibodies had a therapeutic effect by depleting MDSCs in a breast cancer model [227], and myeloid-specific deletion of TGFBR2 reduced tumour metastasis in breast, lung and melanoma models [228]. The gene discussed is TGFB1; the disease is neoplasm.